Exact Sciences Co. (NASDAQ:EXAS) Stock Position Lifted by Walkner Condon Financial Advisors LLC

Walkner Condon Financial Advisors LLC grew its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 6.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,517 shares of the medical research company’s stock after buying an additional 534 shares during the period. Walkner Condon Financial Advisors LLC’s holdings in Exact Sciences were worth $447,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Huntington National Bank lifted its holdings in Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after buying an additional 352 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new position in Exact Sciences during the 3rd quarter worth approximately $34,000. Capital Performance Advisors LLP bought a new position in Exact Sciences during the 3rd quarter worth approximately $35,000. Modus Advisors LLC bought a new position in Exact Sciences during the 4th quarter worth approximately $43,000. Finally, Vestor Capital LLC bought a new position in Exact Sciences during the 3rd quarter worth approximately $46,000. Institutional investors own 88.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on EXAS shares. Benchmark reissued a “buy” rating and issued a $65.00 price target on shares of Exact Sciences in a report on Monday, January 13th. Canaccord Genuity Group cut their price target on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. BTIG Research raised their price target on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Evercore ISI lowered their target price on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Finally, Citigroup lowered their target price on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, Exact Sciences has a consensus rating of “Moderate Buy” and an average target price of $72.76.

Exact Sciences Stock Performance

EXAS opened at $49.31 on Friday. The firm has a market cap of $9.13 billion, a PE ratio of -42.14 and a beta of 1.24. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The business has a fifty day simple moving average of $56.15 and a 200-day simple moving average of $60.09. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.